Thrombosis
Clinical
When is it safe to resume anticoagulation in my patient with hemorrhagic stroke?
Robust scientific data on when to resume anticoagulation after ICH does not exist.
Clinical
Copeptin enhances risk stratification tools in normotensive patients with PE
Does the use of copeptin, either alone or with stratification tools, help identify high-risk patients with pulmonary embolism?
News
COPD linked to higher in-hospital death rates in patients with PAD
COPD was an independent predictor of in-hospital death and of pulmonary embolism in PAD patients.
Latest News for HOSP
CTPA may not rule out VTE in high-risk patients
Does a negative computed tomography pulmonary angiography rule out venous thromboembolism (VTE)?
All Content
VTE prophylaxis often overused in low-risk patients
Is venous thromboembolism (VTE) prophylaxis being appropriately prescribed in hospitalized patients?
Video
DOAC pause yields favorable outcomes for AF patients
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
Video
ARISTOPHANES: Apixaban edges other DOACS for octogenarians
CHICAGO – Insurance claims data from more than 50,000 U.S. octogenarians on a DOAC showed apixaban worked best and caused the fewest major bleeds...
News
ASH releases new VTE guidelines
A panel of the American Society of Hematology released more than 150 recommendations for dealing with venous thromboembolism.
News
All patients with VTE have a high risk of recurrence
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.
News
Apixaban is safest effective DOAC for stroke prevention in Afib, per AHRQ report
The agency found the lowest bleeding risk with apixaban, but cites lack of head-to-head trials as a limitation in evaluating DOACs.